|Position||Trades||Duration||Win rate||Win/loss||Avg win||Avg loss||Return|
|Position||Trades||Duration||Win Rate||Win/Loss||Avg Win||Avg Loss||Return|
Ra Pharmaceuticals Inc (RARX)
Trading: BUY @ $46.99
Signal Strength: STRONG
Indicator can be used in isolation or in additional to another technical indicator to confirmation for trading entry. This indicator has been constructed to highlight the existence of a trend for an assocaited timeframe. Trend determining indicators can be used in short, medium or long term timeframes & determines if the stock is trending or ranging. Once the trend status is quantified, this can then be coupled to additional indicators to add a significant advantage to the trading strategy.
Ra Pharmaceuticals Inc (NASDAQ:RARX) has a medium timeframe uptrend confirmation. This was confirmed through a price breakout on the Dec 27 2019.
The Tricklar medium term trend indicator (TRICK) highlights the peaks and troughs associated with a combination of bars within the first timeframe. As such, successive rallies penetrating preceding higher peaks whilst cancelling preceding low points offer a BULLISH indication in the second time frame. Conversely, failure of rallies to penetrate previous high points whilst maintaining prices below the previous low points indicates BEARISH trends in the second timeframe. The way in which multiple timeframes should be integrated in a complete analysis emphasises an important principle that applies to all technical analysis. The investor should always analyse a market from the big picture down to the level at which trading decisions are made. Trends can exist in many timeframes. Short term trends can therefore be seen together as part of a medium term trend and, in turn, medium trends can be seen together as part of a long term trend.
Calculation: Tricklar medium trend (TRICK):
1) [BULLISH] An uptrend is a succession of higher peaks and higher troughs;
2) [BEARISH] A downtrend is a succession of lower peaks and lower troughs;
PROFILE: Ra Pharmaceuticals Inc (RARX)
Stock Exchange: NASDAQ
Company: Ra Pharmaceuticals Inc
Ticker Codes: | RARX | NASDAQ:RARX |
Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is RA101495, an injection into the tissue under the skin that has completed Phase II clinical trial for the treatment of paroxysmal nocturnal hemoglobinuria (PNH); and is in Phase II clinical trial for treating patients with generalized myasthenia gravis (gMG), as well as in Phase 1b clinical trial for treating atypical hemolytic uremic syndrome (aHUS) and lupus nephritis (LN). The company's preclinical testing products include Factor D inhibition for orphan renal and dense deposit diseases, and C3 glomerulonephritis; Oral C5 inhibitor for PNH, gMG, aHUS, LN, and central nervous system (CNS) diseases; and other complement inhibitors for autoimmune/CNS diseases. It has multi-target collaboration and license agreement with Merck & Co., Inc. Ra Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.
|VRAY Viewray Inc||3.12||6.8||5,344,700||-1||BEARISH|
|NNBR Nn Inc||9.97||4.6||339,800||-1||BEARISH|
|EPZM Epizyme Inc||26.72||4.6||1,255,600||-1||BEARISH|
|CMCO Columbus Mckinnon||39.33||3||200,000||-1||BEARISH|
|YNDX Yandex NV||45.4||2.9||3,327,500||-1||BEARISH|
|BCOM B Communications||1.61||2.5||700||-1||BEARISH|
|SIVB Svb Financial||258.4||2.4||398,400||-1||BEARISH|
|AMD Adv Micro Devices||50.93||2.3||57,722,500||-1||BEARISH|
|AGEN Agenus Inc||3.94||2.3||1,736,600||-1||BEARISH|